Vanqua Bio
Financing Round
- Series B
Round Led by Symbiosis
Founded in 2019, Vanqua Bio is a biopharmaceutical company focused on discovering and developing next-generation medicines for neurodegenerative diseases. Their drug-development approach combines insights into critical neuronal cell pathways with cutting-edge assays. Their lead program targets glucocerebrosidase as a potential treatment for Parkinson’s disease and Dementia with Lewy Bodies. Additional programs address Alzheimer’s and other neurodegenerative diseases.
